Ascletis Announces 3CLpro Inhibitor ASC11 Demonstrated Potential to be Effective Treatment for COVID-19 ...Middle East

- In antiviral cellular assays, antiviral potency (EC90) of ASC11 is 31-fold of that of Nirmatrelvir, 120-fold of that of S-217622, 16-fold of that of PBI-0451 and 7-fold of that of EDP-235. - ASC11 is an in-house discovered oral small molecule drug candidate, targeting 3CLpro, with...

Hence then, the article about ascletis announces 3clpro inhibitor asc11 demonstrated potential to be effective treatment for covid 19 was published today ( Tuesday 19/04/2022 - 12:00 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Ascletis Announces 3CLpro Inhibitor ASC11 Demonstrated Potential to be Effective Treatment for COVID-19 )

Also on site :

• Israel assisted in US rescue mission of downed airman in Iran
• Crew member from downed US fighter jet rescued in 'miraculous' operation, says Trump
• Japan should lead efforts toward U.S.-Iran ceasefire